3.4 kb mitochondrial DNA deletion for use in the detection of cancer

A method is described wherein prostate or breast cancer is detected by quantifying a 3.4-kilobase deletion in the mitochondrial DNA (mtDNA) of a test sample. The deletion is located between nucleotides 10744-14124 of the mitochondrial genome. An increase in the amount of the deletion relative to the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	THAYER, ROBERT, PARR, RYAN, MAGGRAH, ANDREA, REGULY, BRIAN, DAKUBO, GABRIEL D, ROBINSON, KERRY, CREED, JENNIFER
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A method is described wherein prostate or breast cancer is detected by quantifying a 3.4-kilobase deletion in the mitochondrial DNA (mtDNA) of a test sample. The deletion is located between nucleotides 10744-14124 of the mitochondrial genome. An increase in the amount of the deletion relative to the amount of the deletion in non-cancerous prostate and breast tissue is indicative of prostate and breast cancer, respectively. The deletion is detected by detecting the sublimon, i.e. the re-circularized deleted fragment that corresponds to SEQ ID NO:1.